Innovation

Beihang University and International Team Build ‘Machine Eye’ That Reacts Faster Than Humans

Chinese scientists led by Beihang University’s Associate Professor Gao Shuo have developed a “machine eye” that detects moving objects four times faster than current autonomous systems—and faster than human vision. The synaptic transistor array, published in Nature Communications, reduces autonomous vehicle braking distance by 4.4 metres at 80 km/h. Backed by an international team spanning Cambridge, KAUST, and Hong Kong, the hardware plug-in is now in talks with Chinese automotive and drone manufacturers.

Read More...

Egypt’s Arab Organization for Industrialization Unveils 1,800km Hamza-3 Suicide Drone at World Defense Show 2026

Egypt’s Arab Organization for Industrialization (AOI) unveiled its Hamza-3 suicide drone with a 1,800 km range and swarming capabilities in Riyadh. Alongside the Sakr 105 rocket launcher and Haris-2 jammer, the systems highlight a push for localized production, though key components are still imported from China, mirroring a broader Arab drive for defense self-sufficiency.

Read More...

China’s Nuclear Posture Under Scrutiny as US-Russia New START Treaty Collapses

As the US-Russia New START treaty ends, the CTBTO has denied U.S. claims of secret Chinese nuclear tests. Focus shifts to China’s ~600-warhead arsenal, growing by ~100 annually. Beijing rejects trilateral arms talks, citing its smaller stockpile versus America’s 5,000+, framing its build-up as essential “strategic deterrence” amidst a collapsing global arms control framework.

Read More...
3D visualization of the Westlake University super antibody neutralizing the SFTS virus.

Westlake University’s ‘Super Antibody’ ZS1C5 Targets Deadly SFTS Virus with 100% Survival in Animal Trials

Scientists at Westlake University have engineered a “super antibody” that achieved 100% survival in mice exposed to a deadly tick-borne virus. The therapy, called ZS1C5, slashed viral loads in monkeys by 90% in 24 hours, offering the first hope for a targeted treatment against SFTS—a disease with a 30% fatality rate and no current cure.

Read More...